Teva breached Clause 4.1 after DuoResp Spiromax prescribing information was hard to read in sponsored webinar

📊

Key facts

⌄

Case	AUTH/3323/3/20
Complainant	Anonymous (concerned UK health professional)
Company	Teva UK Limited
Material	Recorded sponsored webinar hosted on Guidelines in Practice website
Webinar reference	UK/DUO/17/0047w
Product	DuoResp Spiromax (budesonide/formoterol)
Other product mentioned	Cinqaero (reslizumab)
Issue	Legibility/readability of prescribing information (line length found excessive)
Panel finding	Line length ~150 characters (including spaces) made prescribing information difficult to read
Applicable Code year	2019
Breach clauses	Clause 4.1
Complaint received	12 March 2020
Case completed	8 June 2020
Appeal	No appeal
Sanction	Undertaking received

Reviewed by Dr Anzal Qurbain (FFPM) — ABPI Final Signatory

🤖

Got a question about this case?

Ask one of our 13 specialist ABPI advisors — instant answers, 24/7.

Ask AskAnzal AI

🎬 Expert Video Walkthrough

🎬

Video walkthrough — coming for members

Subscribe now and get expert video analysis for every case as we publish them.

Subscribe — from £299/yr

📋

⌄

A concerned UK health professional complained about the legibility of DuoResp Spiromax (budesonide/formoterol) prescribing information shown in a recorded webinar commissioned by Teva UK Limited (ref UK/DUO/17/0047w) and hosted on the Guidelines in Practice website.
The complainant said the prescribing information was extremely difficult to read due to small text, a dark background and extremely long lines, and was not clear or legible.
The webinar related to implementation of NICE asthma guidelines and included prescribing information for DuoResp Spiromax and Cinqaero (reslizumab).
The Panel assessed the presentation and noted the prescribing information used black text on a flesh-coloured background, but the line length was approximately 150 characters (including spaces).

⚖️

⌄

Breach ruled: Clause 4.1.
The Panel did not find the colour contrast unacceptable.
The Panel could not determine whether font size rendered the text illegible because it did not know what device the complainant used to view the webinar.
The Panel found the line length excessive and that it made the prescribing information difficult to read.
Teva acknowledged the breach.

🔒

Members get the complete breakdown — Clauses, Sanction, Signatory Lens, Audit checklist, and 3 Key Questions.

Best value

£249/year

Annual — save £99

£29/mo

Monthly

Join Now — Instant Access